Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "CSF Receptors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
Owner:RAJAVASHISTH TRIPATHI
Methods and Compositions for Inhibiting Cell Death or Enhacing Cell Proliferation
InactiveUS20100317577A1Inhibit apoptosisEnhance cell viabilityAntibacterial agentsNervous disorderCell survivalBcl-2 Genes
The present invention provides compositions and methods that enhance cell survival. Such compositions feature chimeric polypeptides that include at least a GM-CSF receptor ligand and an anti-apoptotic moiety (e.g., a Bcl-2 protein family member). In one embodiment, the chimeric polypeptide is a GM-CSF-Bcl-xL chimeric polypeptide. The invention further includes methods of using chimeric polypeptides to enhance cell survival or inhibit cell death in a cell at risk of cell death.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Production of ifn-lambda by conventional dendritic cells and uses thereof
ActiveUS20120258082A1Promote absorptionEasy to detectBiocideGenetic material ingredientsConventional Dendritic CellCD8
In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and / or eCD8+ cDCs in the prevention and / or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and / or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and / or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and / or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.
Owner:BAVARIAN NORDIC GMBH
Method of inducing differentiation into myocardial cells using g-csf
InactiveCN101720355AImprove induction efficiencyMammal material medical ingredientsSkeletal/connective tissue cellsCardiac muscleAgonist
Owner:福田惠一
Inhibition of granulocyte colony stimulating factor in the treatment of cancer
InactiveUS20160368980A1Immunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against cell receptors/antigens/surface-determinantsRecurrent CancerAnticarcinogen
The present invention relates to the discovery that granulocyte colony stimulating factor (G-CSF) as well as granulocyte colony stimulating factor receptor (G-CSFR) are highly expressed in cancer tissue and the inhibition of G-CSF using a G-CSF inhibitor, which term includes inhibitors of the G-CSF receptor, represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. G-CSF inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.
Owner:STC UNM
Osteoarthritis treatment
The present invention relates generally to a method for the treatment and / or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.
Owner:UNIVERSITY OF MELBOURNE
Production of IFN-lambda by conventional dendritic cells
In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and / or eCD8+ cDCs in the prevention and / or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and / or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and / or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and / or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.
Owner:BAVARIAN NORDIC GMBH
Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (g-csf)
Described herein are compound for the modulation of the G-CSF receptor. The compounds may act as agonists, antagonists, and / or mixed or partial agonists / antagonists of G-CSF. Further provided herein are methods of treating a condition, including, for example, a neurodegenerative disease, by administering a compound as detailed herein.
Owner:H LEE MOFFITT CANCER CENT & RES INST INC +2
Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
InactiveUS20090215861A1Improve abilitiesReduced activityOrganic active ingredientsSugar derivativesAllergyNucleic acid sequencing
Antisense oligonucleotides for treating and / or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
Owner:PHARMAXIS LTD +1
Treatment for multiple sclerosis
InactiveCN102439039ANervous disorderImmunoglobulins against cytokines/lymphokines/interferonsGM-CSF ReceptorAntibody
Owner:MORFOZIS AG
Soluble Human M-CSF Receptor and Uses Thereof
InactiveUS20100099123A1Increase osteoclast activityBiological material analysisBiological testingDiseaseReceptor for activated C kinase 1
Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease.
Owner:NOVARTIS AG
Soluble human m-csf receptor and uses thereof
InactiveUS20150050280A1Immunoglobulins against cytokines/lymphokines/interferonsSkeletal disorderDiseaseAntiendomysial antibodies
Owner:NOVARTIS AG +1
Osteoarthritis treatment
Owner:UNIVERSITY OF MELBOURNE
Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
Owner:H LEE MOFFITT CANCER CENT & RES INST INC +2
Granulocyte-macrophage colony stimulating factor for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy
Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and / or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
Owner:REPONEX PHARMA APS
Immunodeficient rodent
The purpose of the present invention is to provide a humanized mouse that enables the long-term survival of human hematopoietic stem cells. The present invention is a humanized rodent in which human neutrophils circulate peripherally, and is obtained by transplanting human hematopoietic cells into a human G-CSF gene knocked-in rodent that expresses human G-CSF and does not express rodent G-CSF receptor. The human G-CSF gene knocked-in rodent is an immunodeficient rodent in which a human G-CSF gene has been knocked into the G-CSF receptor gene locus and the function of the G-CSF receptor has been lost.
Owner:CENT INST FOR EXPERIMENTAL ANIMALS
Soluble human m-csf receptor and uses thereof
InactiveUS20140030738A1Biological material analysisBiological testingDiseaseReceptor for activated C kinase 1
Owner:XOMA TECH LTD +1
Use of m-csf for preventing or treating myeloid cytopenia and related complications
ActiveUS20160045567A1Prolong survival timeBiocidePeptide/protein ingredientsHematopoietic stem cell transplantationAgonist
The invention relates to methods and compositions comprising a macrophage colony stimulating factor (M-CSF) polypeptide or an agonist of the M-CSF receptor for preventing or treating myeloid cytopenia and related complications (such as infections) in a patient in need thereof (such as a patient undergoing hematopoietic stem cell transplantation).
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Soluble human M-CSF receptor and uses thereof
InactiveCN103558391ABiological material analysisBiological testingDiseaseReceptor for activated C kinase 1
Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease.
Owner:NOVARTIS AG +1
Treatment For M Treatment For Multiple Sclerosis
InactiveUS20120116059A1Nervous disorderImmunoglobulins against cytokines/lymphokines/interferonsGM-CSF ReceptorAntibody
The present invention relates to methods for the treatment and / or prophylaxis of multiple sclerosis (MS). Antagonists of GM-CSF, such as antibodies specific for GM-CSF or the GM-CSF receptor, are effective in the treatment and / or prophylaxis of multiple sclerosis.
Owner:MORFOZIS AG
Pain treatment
ActiveUS20110287027A1Relieve painGood analgesic effectNervous disorderAntipyreticPreventing painGM-CSF Receptor
The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.
Owner:UNIVERSITY OF MELBOURNE
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
InactiveUS20110262425A1Reduced activityIncrease the number of cellsCompound screeningOrganic active ingredientsBULK ACTIVE INGREDIENTActive ingredient
An objective of the present invention is to provide therapeutic agents for MLL leukemia and MOZ leukemia, which include an M-CSF receptor inhibitor as an active ingredient. Another objective of the present invention is to provide methods of screening for pharmaceutical compositions that treat or prevent leukemia by suppressing the expression or activity of M-CSF receptor. Still another objective of the present invention is to provide methods of testing for leukemia, which include the step of determining the expression level of an M-CSF receptor. The present inventors conducted dedicated studies, and as a result revealed that the M-CSF receptor (M-CSFR, CSF1R, c-FMS, or CD115) is highly expressed in cells having the activity of inducing MLL or MOZ leukemia (leukemia stem cells), both of which are intractable acute leukemia. Specifically, the present inventors discovered that the M-CSF receptor signal is closely associated with the leukemia onset.
Owner:NAT CANCER CENT
Use of M-CSF for preventing or treating myeloid cytopenia and related complications
ActiveUS10709762B2Prolong survival timePeptide/protein ingredientsMammal material medical ingredientsHematopoietic stem cell transplantationAgonist
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Pain treatment
Owner:UNIVERSITY OF MELBOURNE
Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation
InactiveUS7629324B2Avoid reactionTumor suppressionOrganic active ingredientsPeptide/protein ingredientsGM-CSF ReceptorEphA Receptors
The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present invention are used for treating and / or preventing asthma, allergy, hypereosinophilia, general inflammation or cancer. The oligonucleotides of the present invention are more specifically directed against nucleic acid sequences coding for a CCR3 receptor, a common sub-unit of IL-4 and IL-13 receptors, or a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
Owner:PHARMAXIS LTD
Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation
InactiveUS20050282762A1Avoid accumulationAvoid problemsOrganic active ingredientsPeptide/protein ingredientsGM-CSF ReceptorTumor cells
The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present invention are used for treating and / or preventing asthma, allergy, hypereosinophilia, general inflammation or cancer. The oligonucleotides of the present invention are more specifically directed against nucleic acid sequences coding for a CCR3 receptor, a common sub-unit of IL-4 and IL-13 receptors, or a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
Owner:PHARMAXIS LTD
Method of treating pain using an antagonist of GM-CSF
The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.
Owner:UNIVERSITY OF MELBOURNE
Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct
PendingUS20210070851A1Immunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against cell receptors/antigens/surface-determinantsHematopoietic cellAntiendomysial antibodies
Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.
Owner:UNIV ZURICH
Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation
InactiveUS20100286239A1Avoid reactionTumor suppressionOrganic active ingredientsPeptide/protein ingredientsEphA ReceptorsGM-CSF Receptor
The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present invention are used for treating and / or preventing asthma, allergy, hypereosinophilia, general inflammation or cancer. The oligonucleotides of the present invention are more specifically directed against nucleic acid sequences coding for a CCR3 receptor, a common sub-unit of IL-4 and IL-13 receptors, or a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
Owner:TOPIGEN PHARMA INC
Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
InactiveUS8119790B2Improve stabilityImprove efficiencySugar derivativesAntipyreticAllergyGM-CSF Receptor
Owner:PHARMAXIS LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com